Must See Spirit of the Season Eye & Lip Art

'Tis the season for holiday eye and lip art. Instagram is bursting with unbelievable artistry. We are so inspired by the flow of creativity and the looks that can be achieved using Mehron products. The ability of the talented artists to create intricate detail on such a tiny canvas is nothing short of amazing. In the words of Buddy the Elf, "The best way to spread Christmas cheer is singing loud for all to hear." So we want to sing the praises of these artists for everyone to hear, hoping to spread inspiration by sharing their holiday and winter artistry. We wish we could feature each and every one of you, but the posts would never end! Here are some of the looks that truly wowed us. Most of the products used to create theare available as part of our Holiday Sale.

Click on the image to visit the artist's Instagram page.

sunnymint7 using Paradise Makeup AQ, Copper Metallic Powder and Mixing Liquid
Chelsea Derber using Paradise Makeup AQ in White
pigeon_pie_art using AdGem and Paradise Makeup AQ in Teal, White, Black, Yellow, Red and Green
sunnymint7 using Paradise Makeup AQ
Chelsea Derber using Paradise Makeup AQ in Lagoon Blue, Light Blue and White
Soolmoz Taylor using Paradise Makeup AQ in Blue, Black, White, Yellow and Brown
sunnymint7 using Metallic Powder in Gold and Mixing Liquid
hannarig_ using Paradise Makeup AQ 
Brianna Bisson using Mixing Liquid
Jessica Scoles using Paradise Makeup AQ
Adrianna Lebron using iNtense Pro Pigment in Mountain Moss
Jessica Scoles using Paradise Makeup AQ
sunnymint7 using Paradise Makeup AQ

read more...

DeVry Education Group, Owner of American University of the Carrbbean and Ross University Schools of Medicine, Settles Allegations of Deceptive Marketing

The parade of legal settlements made by large health care organizations just keeps stepping along.  The latest entry in it was DeVry Education Group, which owns two for-profit offshore (from the US and Canada) medical schools: American University of the Caribbean School of Medicine, and Ross University School  of Medicine.

The Case

In early 2016, we first discussed the deceptive marketing charges against DeVry University and DeVry Education Group here.  The charges have now been settled. The lede of the AP story about the settlement (via ABC News) was:

DeVry University and its parent company are paying $100 million to settle a federal lawsuit alleging the school misled students through deceptive ads.

The allegations that led to the settlement were:

The lawsuit focused on two marquee ad claims that DeVry used for years but dropped in October in a settlement with the U.S. Education Department.

Since at least 2008, the chain had advertised that 90 percent of its graduates who actively sought employment landed jobs in their field within six months of graduation.

But federal investigators found that DeVry was counting students who found jobs outside the fields they studied, and who already had jobs before they enrolled.

Included in the statistic was a graduate who studied in the health care field but found work as a restaurant server and another who worked as a car salesman, according to the FTC lawsuit.

The commission also challenged a claim that DeVry graduates earn 15 percent more than alumni at other schools a year after graduation.

So these were relatively straightforward allegations of deceptive marketing. The penalties included fines for the company as a whole.

Under the settlement, DeVry agreed to pay more than $49 million to the FTC, which says it will distribute the money to students 'harmed by DeVry's conduct.'

The chain also agreed to forgive more than $30 million in loans issued before September 2015, and $20 million in debt owed by former students.

Also,

Going forward, DeVry has promised not to misrepresent job and income prospects of potential students, and not to count jobs that students found more than six months before graduation.

That seems a bit strange, because

officials for Devry, which is based in Downers Grove, Illinois, denied all wrongdoing but said they are 'pleased this matter is reaching resolution.'

If there was no wrongdoing, why did they need to pledge no further wrongdoing? In fact, if there was no wrongdoing, why did company management agree to pay $100 million? It seems to me that if there was no good evidence supporting the charges, the company could have defended the suit for a lot less than that.

Of course, the managers knew that the settlement would be paid by other peoples' money. As is usually the case nowadays, it did not include any negative consequences for any company managers who might have enabled, authorized, directed or implemented any deceptive marketing.

The Implications

So once again we have an example of a legal settlement involving a large, US based health care related - at least in part - organization.  The settlement involved allegations of unethical behavior that likely harmed students.  Yet the amount of the settlement amounted to a slap on the wrist for a corporation with over $1.8 billion in revenue (2015-2016, per Yahoo).  Furtheremore, the nature of the settlement demonstrated the continued impunity of managers of large health care organizations, none of whom in this case had to suffer any negative consequences, yet some must have enabled, authorized, directed or implemented the deceptive marketing. 

This case also raises even more questions about the American (and to some extent Canadian) reliance on offshore, for-profit medical schools to train many of their physicians.  As we have frequently discussed, (most recently here),...

 Admission to US medical schools is increasingly difficult.  So many who seek medical careers may be tempted to apply to schools outside the US.  In the last 30 years, American entrepreneurs have opened offshore medical schools, mostly in the Caribbean, that cater to US students.  They teach in English, and do not require immersion in an unfamiliar culture, so may be more attractive than medical schools in other countries whose mission is to educate physicians to practice in those countries. In 2010, Eckhert documented that the number of offshore medical schools, "for-profit institutions whose purpose is to train U.S. and Canadian students who intend to return home to practice," but not to train physicians to practice in the countries in which these schools are located, was rapidly growing.(1)  By 2010, there were 33 such schools, 20 of which were new since 2000.

Such offshore medical schools exist in a grey area.  The small countries or colonies in which they are located usually do not seek to regulate them, since the physicians they produce are going to practice elsewhere. There is no requirement that these offshore medical schools be accredited in the US.  Such  accreditation is currently not required for individual graduates of such schools to be admitted to US house-staff programs or for US licensure.  So perhaps it is not surprising that little is known about these schools.

How they choose students, the qualifications or even names of their faculty, their curriculum, how they supervise clinical training (which is mostly done by affiliated North American hospitals), and what happens to their graduates are obscure.  Eckhert attempted to describe what is known, but noted "variability exists in the availability of information on faculty; where data exists, it is noted that most of the permanent on-site basic science faculty are internationally trained, many have no documented medical education experience in the United States, and it is not uncommon for them to be OMS [offshore medical school] alumni."

Concerns about how offshore medical schools are run, and how well they educate their students can only be heightened by the settlement of the latest DeVry case.

The DeVry statement about the settlement included the assertion that "at no time has the academic quality of DeVry University education been questioned."  This is a bit disingenuous.  The case was brought by the Federal Trade Commission, which has no particular role overseeing educational quality, and was specifically about deceptive marketing.

One wonders, however, what sort of education might be provided by a large corporation whose corporate culture did not recoil from what appeared to be grossly deceptive marketing.

That statement also specifically only mentioned DeVry University, which is one of many for-profit "educational" organizations under the Devry umbrella (look here).  It said nothing about how such a corporate culture might affect educational quality at the other subsidiaries. 

It certainly did nothing to help answer questions that were previously raised about the two DeVry owned and operated for-profit medical schools.  In 2013, we posted about a Bloomberg investigative article about the two DeVry owned medical schools, at the American University of the Caribbean and Ross University.  The article focused on multiple issues:
-  high attrition rates of students compared to those in US based schools
-  inability of many students to complete clinical training in the customary two years
-  low rates of students matching to US residencies compared to US graduates
-  high costs for students, presumably a cause of their high levels of debt

Keep in mind that some of these concerns were based on statistics supplied by DeVry.  Yet now there is a new reason to be doubtful about their statistics, and any other information coming out of DeVry about its medical education offerings.  Furthermore, while Eckhert wrote in 2010 that the increasing presence of offshore medical graduates in the US "obligates U.S. medicine to take a closer look at these educational programs," no such scrutiny has occurred since then.

So, we see another aspect of the US health care system in which money seems to trump mission, facilitated by an unseemly alliance between wealthy corporate executives and bad US government policy.  We need to reexamine our fascination for "market based" approaches to health care, when almost nothing about any part of health care resembles, or could resemble a free market.  We need to make health care more transparent, and shine more sunshine on the nooks and crannies, like off-shore but US corporate owned medical schools.  We need to facilitate health care leadership and governance that puts patients' and the public's health first, way ahead of the personal enrichment of the participants.

This may be a pipe dream in 2016, since the US at least just voted in what seems to be the most market fundamentalist, plutocratic administration yet.  As the AP article noted, "some for-profit colleges see President-elect Donald Trump as a champion of the private sector who could spur a rebound for the [for-profit education] industry.  In the weeks after Trump's election, sharing in DeVry's parent company surged 30 percent."
 
Thus, as long as the US continues its light touch regulation if, or even further deregulates the outsourced offshore system which now educates increasing numbers of US doctors(2), Americans who want to become doctors ought to be very skeptical about the futures they may face if they choose to go to such offshore schools.

References

1.  Eckhert NL.  Private schools of the Caribbean: outsourcing medical education.  Acad Med 2010; 85: 622-630.  Link here.
2.  Eckhert NL, van Zanten M.  U.S.-citizen international medical graduates - a boon for the workforce? N Engl J Med 2015; 372: 1686-7.  Link here.

read more...

Festive Holiday Body Art

Some people express their holiday spirit by decorating with lights, trees, and ribbons galore. Others, make countless Christmas cookies or sing carols for all to hear. And then there are the body artists. These men and women bring the magic of the season to life as they put paint to brush. Their vibrant iconic characters and festive looks stir up wonder and joy. As we perused our social media channels, we were inspired by so many works of art. We thought we would spread some holiday cheer by sharing them here! If you are looking for products to recreate the looks, you will find great prices on our Paradise Makeup AQ Holiday Bundles.

Click on the graphic to visit the artist's Instagram page.

https://www.instagram.com/jordanhanz/
Jordan Hanz using Paradise Makeup AQ in Beach Berry and Red

Rupinder Ashan using Paradise Makeup AQ for most of the look
Picturresque using Metallic Powder in Silver
Brenna Mazzoni using Paradise Makeup AQ
Rachael Trudell using Green Fantasy F-X Makeup
Meagan Lee Emerson 
Raven George using Paradise Makeup AQ
ellie35x using Paradise Makeup AQ and Paradise AQ Glitters
Mille Viola Schmidt using Paradise Makeup AQ in White
ladyparadoxx using Paradise Makeup AQ in White, Black, Orange and Yellow
noeldembo using Paradise Makeup AQ
Daniel Ruiz Smith using Paradise Makeup AQ in White
Paris Stafford
shannon_glam using Paradise Makeup AQ 8-Color Palette
ellie35x using Paradise Makeup AQ
Josie English using Paradise Makeup AQ
imogenhearts using Paradise Makeup AQ in Red and Dark Red

A HUGE thank you to all the artists who are making the holidays a little happier with their festive body painting.
read more...

Suppose the Pope Condemned Health Care Corruption - and Hardly Anyone Noticed?

Introduction - Health Care Corruption as a Taboo Topic

We have frequently discussed outright corruption in health care as one of the most important causes of health care dysfunction.  Transparency International (TI) defines corruption as
Abuse of entrusted power for private gain

In 2006, TI published a report on health care corruption, which asserted that corruption is widespread throughout the world, serious, and causes severe harm to patients and society.
the scale of corruption is vast in both rich and poor countries.

Also,
Corruption might mean the difference between life and death for those in need of urgent care. It is invariably the poor in society who are affected most by corruption because they often cannot afford bribes or private health care. But corruption in the richest parts of the world also has its costs.

The report did not get much attention.  Since then, health care corruption has been nearly a taboo topic in the US.  When health care corruption is discussed in English speaking developed countries, it is almost always in terms of a problem that affects benighted less developed countries.  On Health Care Renewal, we have repeatedly asserted that health care corruption is a big problem in all countries, including the US, but the topic remains anechoic.

Yet somehow, a substantial minority of US citizens, 43%, seemed to believe that corruption is an important problem in US health care, according to a TI survey published in 2013 (look here).  But that survey was largely ignored in the media and health care and medical scholarly literature in the developed world, and when it was discussed, it was again in terms of results in less developed countries.  Health Care Renewal was practically the only source of coverage in the US of the survey's results.

"Corruption is Cancer to Health Industry, Pope Tells Hospital Staffers"

Yesterday, this story appeared in the Catholic News Service. It opened with:

VATICAN CITY (CNS) -- Corrupt business practices that seek to profit from the sick and the dying are a cancer to hospitals entrusted with the care of the most vulnerable, especially children, Pope Francis said.

Doctors, nurses and those who work in the field of health care must be defined by their ability to help their patients and be on guard against falling down the slippery slope of corruption that begins with special favors, tips and bribes, the pope told staff and patients of Rome's 'Bambino Gesu' children's hospital Dec. 15.

'The worst cancer in a hospital like this is corruption,' he said. 'In this world where there is so much business involved in health care, so many people are tricked by the sickness industry, 'Bambino Gesu' hospital must learn to say no. Yes, we all are sinners. Corrupt, never.'

One might think that this condemnation of health care corruption by the leader of a huge Christian religious group would get considerable attention, but one would be wrong. The only other coverage of the Pope's message was an extremely brief (6 sentences) item by the AP (see here via Business Insider.)

Note that Pope Francis not only condemned corruption in the strongest terms, but he linked it the transformation of medicine and health care into a business, with the presumptive result in an era of the "shareholder value principle" that revenue has become more important than caring for patients.  He also implied that the road to corruption begins with conflicts of interests.

Note that Pope Francis' predecessor, Pope Benedict XVI, also decried the transformation of medicine and health care into a business.  As we noted here, he wrote

during the current economic crisis 'that is cutting resources for safeguarding health,'... Hospitals and other facilities 'must rethink their particular role in order to avoid having health become a simple 'commodity,' subordinate to the laws of the market, and, therefore, a good reserved to a few, rather than a universal good to be guaranteed and defended,'

Furthermore,

'Only when the wellbeing of the person, in its most fragile and defenseless condition and in search of meaning in the unfathomable mystery of pain, is very clearly at the center of medical and assisted care' can the hospital be seen as a place where healing isn't a job, but a mission,...

Pope Benedict's call for health care to be restored to being a calling, not a business, remained anechoic too.   

Discussion

Recently, I became just a bit more optimistic that health care corruption would start getting the attention it deserved.  That may have been premature.  The world seems to becoming ever more friendly to market fundamentalism or neoliberalism.  The notions that every human activity, including medicine and health care, should be conducted as a business, and that in business, revenue come first is likely to be helped by the election of an ostensibly billionaire businessman to the presidency of the US.  That said president-elect once called Pope Francis "disgraceful" after the Pople questioned how Trump's proposal to "build a wall" to keep out supposedly deplorable Mexican immigrants squared with Christian beliefs (look here).

Yet as suggested by the recent Transparency International report on corruption in the pharmaceutical industry,  there is so much money to be made through pharmaceutical (and by implication, other health care corruption) that the corrupt have the money, power, and resources to protect their wealth accumulation by keeping it obscure.  In the TI Report itself,


However, strong control over key processes combined with huge resources and big profits to be made make the pharmaceutical industry particularly vulnerable to corruption. Pharmaceutical companies have the opportunity to use their influence and resources to exploit weak governance structures and divert policy and institutions away from public health objectives and towards their own profit maximising interests.

Keep in mind that the money made from corruption does not just go to innocent peoples' retirement funds that are invested in pharmaceutical stocks.  It predominantly goes to top corporate executives and managers, and their cronies who preside over the corrupt practices.


I might as well repeat myself once again.  As I wrote in 2015,

If we are not willing to even talk about health care corruption, how will we ever challenge it? 

So to repeat an ending to one of my previous posts on health care corruption....  if we really want to reform health care, in the little time we may have before our health care bubble bursts, we will need to take strong action against health care corruption.  Such action will really disturb the insiders within large health care organizations who have gotten rich from their organizations' misbehavior, and thus taking such action will require some courage.  Yet such action cannot begin until we acknowledge and freely discuss the problem.  The first step against health care corruption is to be able to say or write the words, health care corruption.


read more...

New Year's Eve Makeup Looks That Will Bring Out Your Inner Sparkle


This New Year's Eve it won't be only your glass of bubbly that's sparkling. We've called on makeup artist Rachel Estabrook to help us create two looks that will have you glistening as you ring in 2017. And you can find the products you need to create them in our special New Year's Eve collections.

Sexy and Sparkly



  • Start with your favorite base and contour.
  • Apply iNtense Pro Pigment in Carbon over the lid and along the lower lash line. Blend out softly all around the eye for a blurry, smokey effect.
  • Add a pop of highlight to the inner corner of the eyes, along the brow bone, and upper cheek bones with Precious Gem Powder in Diamond.
  • Complete the dramatic eye with Fuller E.Y.E Lashes. Apply using AdGem so they stay in place for an extra long evening of celebration.
  • Now for the full glitter lip! Using a brush, apply L.I.P Cream in Cherry Chocolate. Then pat on Paradise Glitter in Cabernet. 
  • For some added festive fun, use the AdGem to add a rhinestone beauty mark.

All products are included in our Midnight Kiss Collection.

Soft and Shimmery



  • Create a flawless canvas with your favorite foundation.
  • Build up E.Y.E Powder in Espresso on the upper outside of the top lid and blend up and out for an open eye look. Use this same shade to line the bottom lash line - but only half-way across the eye - and blend for a soft smoke underneath the eye.
  • Apply Precious Gem Powder in Champagne to the center of the lid, blend into the Espresso. Keep the Champagne impactful for a highlight and pop of color, adding to the inner corner of the eyes as well.
  • Define the eye with Full E.Y.E Lashes. Apply with AdGem for lashes that last all night long.
  • Brighten up the look with a fun, shimmery lip. Use a brush to apply L.I.P Cream in Petal Pink. Follow with a touch of Paradise Glitter in Pastel Pink to the center of both the top and bottom lip.

All products are included in our Champagne Toast Collection.

Model: L.J. Wright
read more...

Despite Long Record of Misadventures, Johnson and Johnson to Receive Award for "Ethical Leadership?!"

What does it take for a big pharmaceutical/ device/ biotechnology company to get an ethics award?

Reported by Sheila Kaplan at Stat (but for subscribers only), and first noticed by Carl Elliott and just discussed on his Fear and Loathing in Bioethics blog, it appears that the giant Johnson and Johnson pharma/ device/ biotech company will get an award in "ethical leadership" from and "organization called Fellowships at Auschwitz for the Study of Professional Ethics, or FASPE."

The Stat report, quoted by Dr Elliott, stated:

FASPE Chairman David Goldman, an attorney in New York, said he was aware of the pharma giant’s various ethical tangles, but believes the company has moved beyond them. 'We do think they’ve acknowledged their failures and taken the apropriate steps to resolve them,' he said. 'They know what they’ve done; we talked to them about it and they’ve taken the right action.'

However,

Others disagree, noting that in 2013, J&J and its subsidiaries agreed to pay $2.2 billion to resolve criminal and civil allegations of improperly promoting several prescription drugs, including paying kickbacks to physicians. That was one of the largest health care fraud settlements in US history. The company has also lost recent product liability cases involving allegations of its talcum powder causing ovarian cancer.

If only it were just that.

In fact, we have been writing about the ethical misadventures of Johnson and Johnson for a long time.  Our collected posts are here.  An updated version of their legal record since 2010 is at the end of this post. Their misadventures go well beyond those listed in the Stat article, and new cases of them have been appearing regularly, most recently this year.

Perusing the list suggests that this giant company (with about $70 billion in yearly revenue) is a poster child for bad behavior by health care organizations.  Despite the multitude of allegations leading to settlements, and sometimes findings of guilt, the company has never faced a penalty of significant size, given its revenue.  Furthermore, almost no company leaders who enabled, authorized, directed or implemented the various misadventures have suffered any negative consequences, therefore appearing to enjoy impunity

There are many more examples on this blog of legal settlements, and even episodes involving bribery, fraud, kickbacks, and other crimes that demonstrate the continuing impunity of leaders of large health care organizations.  It is likely that such impunity has led to the general concerns that the system is "rigged" in favor of the wealthy, the well-connected, and the insiders. 

(And now we have a president-elect who has promised to act against the "rigged system," but seems to be bent on appointing wealthy, well-connected people to run his executive branch, but in any case, as we have said before...)

We once again see the perverse incentives at work that drive bad behavior by health care oragnizational leaders.  One can obviously become very rich by directing this bad behavior.  Up to now, the likelihood that one would eventually pay any penalty for doing so was tiny.  Now it is slightly higher.  Whether those up the ladder, who might have authorized the behavior, turned a blind eye to it, or avoided enquiring about anything that could be bad behavior, as long as the money came in, will suffer any negative consequences from these actions or inactions in the future is still unclear.

We will not make any progress reducing current health care dysfunction if we cannot have an honest conversation about what causes it and who profits from it.  True health care reform requires ending the anechoic effect, exposing the web of conflicts of interest that entangle health care, publicizing who benefits most from the current dysfunction, and how and why.  But it is painfully obvious that the people who have gotten so rich from the current status quo will use every tool at their disposal, paying for them with the money they have extracted from patients and taxpayers, to defend their position.  It will take grit, persistence, and courage to persevere in the cause of better health for patients and the public. 


 Appendix - Johnson and Johnson Legal Record since 2010
 2010
- Convictions in two different states for misleading marketing of Risperdal
- A guilty plea for misbranding Topamax
2011
- Guilty pleas to bribery in Europe  by Johnson and Johnson's DePuy subsidiary
- A guilty plea for marketing Risperdal for unapproved uses  (see this link for all of the above)
- A guilty plea to misbranding Natrecor by J+J subsidiary Scios (see post here)
2012 
 - Testimony in a trial of allegations of unethical marketing of the drug Risperdal (risperidone) by the Janssen subsidiary revealed a systemic, deceptive stealth marketing campaign that fostered suppression of research whose results were unfavorable to the company, ghostwriting, the use of key opinion leaders as marketers in the guise of academics and professionals, and intimidation of whistleblowers. After these revelations, the company abruptly settled the case (see post here).
-  Johnson & Johnson was fined $1.1 billion by a judge in Arkansas for deceiving patients and physicians again about Risperdal (look here).
-  Johnson & Johnson announced it would pay $181 million to resolve claims of deceptive advertising again about Risperdal (see this post).
2013
-  Johnson & Johnson settled case by shareholders alleging that management made misleading statements and withheld material information about manufacturing problems (see this post)
-  Johnson & Johnson Janssen subsidiary pleaded guilty to a charge of misbranding Risperdal, and settled for a total of $2.2 billion allegations that it promoted the drug for elderly demented patients and adolescents without an indication, and despite evidence of its harms (see this post).
 -  Johnson & Johnson DePuy subsidiary agreed to settle with multiple plaintiffs for $2.5 billion allegations that it sold defective mental-on-metal artificial hip, and hid evidence of its harms .
- Johnson & Johnsonn Janssen subsidiary was found by two juries to have concealed harms of its drug Topamax (see this post for this and above case).
- Johnson & Johnson Ethicon subsidiary's Advanced Surgical Products and two of its executives agreed to settle charges by US FDA that is sold mislabeled products used to sterilize equipment such as endoscopes (see this post).
- Johnson & Johnson fined by European Commission for anticompetitive practices, that is, collusion with Novartis to delay marketing generic version of Fentanyl (see this post).
2014 
- Johnson & Johnson DePuy subsidiary settled Oregan state charges that it marketed the ASR XL metal-on-metal hip joint prosthesis without disclosing its high failure rate (see this post).
2015
-  Johnson & Johnson found by jury to have concealed harms of Risperdal.
-  Johnson & Johnson Ethicon subsidiary found by jury to have concealed harms of its vaginal mesh device.
-  Johnson & Johnson McNeil subsidiary pleaded guilty to marketing adulterated Tylenol. (see this post for three items above.)
2016
- Johnson & Johnson subsidiary Aclarent settled allegations that it sold its Stratus device for unapproved uses.  Two former executives of that subsidiary also were found guilty of distributing misbranded and adulterated devices (see this post

read more...

Ring In The New Year With These Shimmery Makeup Collections


Look your best on the biggest night of the year! This New Year's Eve put your regular makeup routine to sleep and get glamorous with the help of two gorgeous collections. December 31st is all about festive and fun looks. Whether you wish to go bold and sophisticated or soft and flirty, these two bundles contain everything you need to glam it up with some glitter and glimmer - at discounted prices.
Champagne Toast Collection
A $51 Value!
  Special New Year’s Collection Price: $42.95

Start off your New Year celebration with a champagne toast and shimmering champagne lids to match. The soft shades in the Champagne Toast Collection will bring out your inner sparkle. Create a subtle look to highlight your eyes or perfect your pout with some pastel pink glitter to complement your pink champagne. Toast to a new year and a new you with: .17 oz. Champagne Precious Gem Powder, .14 oz. Expresso E.Y.E Powder, .14 oz. Petal Pink L.I.P Cream, .25 oz. Pastel Pink Paradise Glitter, Full E.Y.E Lashes, and AdGem 12 Rhinestones and .125 oz. Adhesive.
Midnight Kiss Collection
A $53 Value!
  Special New Year’s Collection Price: $42.95

The countdown is on! The Midnight Kiss Collection has bold, daring, and sophisticated colors for your most adventurous New Year's celebration yet! Create mysterious smokey eyes and glistening bold lips with added sparkle. Ring in a romantic new year with: .17 oz. Diamond Precious Gem Powder, .11 oz. Carbon iNtense Pro Pigment, .14 oz. Cherry Chocolate L.I.P Cream, .25 oz. Cabernet Paradise Glitter, Fuller E.Y.E Lashes, and AdGem 12 Rhinestones and .125 oz. Adhesive.

Don't miss our next blog post, which will show you how to create some amazing looks for New Year's Eve celebrations.

read more...

Our Holiday Appeal: Speaking Out on Conflicts of Interest, Corruption, and Attacks on Science Since 2003

In 1998, I learned of the plight of Dr David Kern, my colleague and friend at Brown.  Dr Kern ultimately lost his job because a local company took offense when he presented data about a new occupational disease that occurred at the company's factory (see summary here).  Thus I was alerted to the growing dysfunction of US health care. 

To better understand health care dysfunction, I interviewed doctors and health professionals, and published the results in Poses RM.   A cautionary tale: the dysfunction of American health care.  Eur J Int Med 2003; 14(2): 123-130. (link here).  In that article, I postulated that US physicians were demoralized because their core values were under threat, and identified 5 concerns: 1. domination of large organizations which do not honor these core values 2. conflicts between competing interests and demands 3.  perverse incentives4. ill-informed, incompetent, self-interested, or even corrupt leadership 5.  attacks on the scientific basis of medicine


Since then, my colleagues, some of who were original interviewees, and I have tried to raise awareness of these and related issues, now mainly through the Health Care Renewal blog.   For a long time, many of these issues remained relatively anechoic, partly because discussion of them offended those with vested interests in keeping the system the way it was.  After the economic crash of 2008, we began to realize that related issues were causing wider dysfunction, in the political economy, in the US and globally.

Who would have thought, though, that such issues would be in headlines every day, mainly pertaining to a presidential campaign, and now the presumptive incoming US administration?  Conflicts of interest, corruption, attacks on science, and even attacks on just plain facts are the stories of the day.  But you heard it here first on Health Care Renewal.

Maybe this will lead to some progress now on health care dysfunction, if the world does not blow up.

On that happy note, in this holiday season, I once again ask for contributions to FIRM - the Foundation for Integrity and Responsibility in Medicine.  We set up FIRM,  a US non-profit organization, to try to provide some financial support for HCR.   Despite the grandiose name, FIRM does not have an endowment, and is almost exclusively dependent on individual contributions.  (In the US, charitable foundations interested in health care or ethics seem to also regard health care corruption as a taboo topic, and have not been exactly forthcoming.)  So please consider contributing to FIRM.  FIRM is a US 501(c)3 non-profit organization, and so if you are in the US, contributions may be tax deductible according to US law.  Please send contributions to FIRM at 16 Cutler St, Suite 104, Warren, RI, 02885, and any questions or comments to me by email, rposes at firmfound dot org.

read more...

Efficacy, We Don't Need No Stinking Proof of Efficacy - Says Apparent Trump Candidate to Lead FDA

Multiple media reports suggest that US president-elect Donald Trump is considering a most unusual candidate for commissioner of the Food and Drug Administration (FDA).  The basics, as reported by Bloomberg:

President-elect Donald Trump’s transition team is considering a Silicon Valley investor close to billionaire Peter Thiel to head the Food and Drug Administration, according to people familiar with the matter.

Jim O’Neill, the Thiel associate, hasn’t been officially selected, according to the people, who asked to remain anonymous because the decision process is private, and the Trump team could still go in another direction.

O’Neill is a managing director at Thiel’s Mithril Capital Management, and last served in government during the George W. Bush administration as principal associate deputy secretary at the Department of Health and Human Services. He’s also a board member of the Seasteading Institute, a Thiel-backed venture to create new societies at sea, away from existing governments.

Thiel’s spokesman Jeremiah Hall said O’Neill is a good candidate. 'Jim O’Neill has extensive experience in government and in Silicon Valley. He is a strong candidate for any of several key positions,' Hall said in an e-mail. Separately, Politico and CNBC reported that O’Neill could be under consideration for various positions.

Mr O'Neill would be a very unusual candidate to lead the FDA

Ill-Informed

Mr O'Neill has no medical, health care, or biomedical research background.  As Bloomberg noted, "the head of the FDA for the last five decades has either been a trained physician or a prominent scientific researcher."   However, Mr O'Neill's relevant track record is that he

did his undergraduate studies at Yale University, where he was a member of the concert band and played the horn, and has a masters degree from the University of Chicago, both in the humanities. He joined the Health and Human Services Department under Bush in 2002, first as a speechwriter, rising in the final years of the administration to head some policy functions,...

We have frequently discussed how current leaders of health-care organizations are often ill-informed about biomedical science, health care, medicine, public health and related issues.  Mr O'Neill would fit right in with them were he to run the FDA.  

About to Transit the Revolving Door

Mr O'Neill seemed to be on Mr Trump's radar since he was "a close associate of [Trump confidant Peter] Theil for nearly a decade." More recently, Mr O'Neill

served as a managing director at Clarium Capital -- Thiel’s hedge fund that made a mint by correctly predicting the housing bubble and then crumbled -- and since 2012 has worked at Mithril Capital, Thiel’s late-stage venture firm, where he is a managing director.

His recent work would imply that to become FDA commissioner would transit the revolving door.  As reported by the International Business Times,

'He brings strong ties to industry and would reflect a tremendous bias in their favor at the FDA,' Dr. Michael Carome, director of the public health research group at the consumer watchdog Public Citizen, told International Business Times. 'He’s senior executive in a hedge fund investing in medical healthcare products. That alone should be disqualifying.'


In particular,

In the private sector, O'Neill has a clear financial stake in the outcome the regulatory process — a process he could oversee as head of the FDA.

For example, in 2014, Mithril invested $15 million in the German medical device company MagForce which manufactures cancer treatment technologies — in exchange for 23 percent ownership in its U.S. subsidiary. In June, the company announced it filed for an 'Investigational Device Exemption' with the FDA — basically a permit to use its unapproved product to gather evidence for clinical trials. MagForce’s profitability could very well hinge on how the FDA regulates its products: According to 2015 financial filings, MagForce is 'working with the FDA to update preclinical studies, which were conducted approximately ten years ago, to current US regulatory standards.'

Challenging Evidence-Based Medicine, with Dangerous Implications

Perhaps because of his lack of understanding of health care and medicine, and his financial interests, Mr O'Neill has advocated for radical changes at the FDA, particularly for allowing drugs and devices to be marketed without any good evidence of their efficacy, that is, that they provide any benefits to patients.

 In a 2014 speech, he said he supported reforming FDA approval rules so that drugs could hit the market after they’ve been proven safe, but without any proof that they worked, something he called 'progressive approval.'

'We should reform FDA so there is approving drugs after their sponsors have demonstrated safety -- and let people start using them, at their own risk, but not much risk of safety,' O’Neill said in a speech at an August 2014 conference called Rejuvenation Biotechnology. 'Let’s prove efficacy after they’ve been legalized.'

It might sound plausible, at least if you know nothing about medicine.

The big problem with it is, as I was taught in medical school, that all medical interventions, including drugs and devices, have their risks.  No intervention is free of all potential to cause harm.  So we advocates of evidence-based medicine suggest that no intervention should be given to patients without clear evidence that its benefits outweigh its harms.  You cannot show benefits outweigh harms without having some good evidence about benefits.

Even big pharma has become reconciled to this notion.  An article in the Hill quoted one Mr Peter Pitts thus,

'People need to understand that safety doesn’t exist without the balance of risk,' said Peter Pitts, president of the Center for Medicine in the Public Interest and a former FDA associate commissioner under President George W. Bush.

He said that 'every drug has risks,' so the important consideration is balancing the risks against how effective the drug will be. Side effects that would never be approved for Aspirin might be approved for a lung cancer drug, he noted.

And this from someone who did public relations for big pharma for a long time (look here).  Mr Pitts still works for CMPI, which historically obtained much of its money from the pharmaceutical industry (look here). 

Furthermore, the studies of treatments usually done prior to efficiacy trials are not designed to assure their safety, just that they do not have catastrophic adverse effects for a lot of patients.  Phase I and II trials do not enroll enough patients or follow them long enough to rule out rare but dangerous adverse effects occurring early, or any adverse effects occurring late.

So the International Business Times noted that

Dr. Aaron S. Kesselheim, associate professor of medicine at Harvard Medical School and the director of Brigham and Women’s Hospital program on regulation, therapeutics, and law, says O’Neill’s proposals could transform the drug market into an unregulated space that resembles the vitamin and supplement market. 'You’d have all these expensive products out there without being shown to work while presenting substantial safety risks — and being pushed on physicians and patients by overzealous marketing,' Kesselheim told IBT.

'He’s coming at things from an agenda-driven and non-evidence -based point of view,' Kesselheim said. 'That should be very scary for patients and physicians.'
By the way, this just underlines just how Mr O'Neill would be a prototypical ill-informed leader were he to be appointed to run the FDA.

Also, per the Hill article,

Dr. Michael Carome, director of Public Citizen’s health research group, said he was 'just stunned' when he heard O’Neill’s name reported to be in consideration for FDA.

He said O’Neill’s proposals would bring the country back to 19th century 'snake oil salesmen' being able to fool people into using ineffective products.
Just to ice the cake, O'Neill's bright idea would apparently violate the law.  As Matthew Herper wrote in Forbes,

the 1962 Kefauver amendment ... said drugs must be proved safe and effective before they can be sold. This law was put in place after an FDA reviewer kept a drug for morning sickness, thalidomide, from being sold in the U.S. The medicine caused birth defects in the rest of the world.
So not only would Mr O'Neill be an tremendously ill-informed leader of the FDA, he has the potential of being a prototypically mission-hostile leader were he to try to carry out his idea of eliminated prospective efficacy testing.  We have also frequently written about the havoc that can be wrecked on health care by such leaders.

So Mr O'Neill's bright idea would effectively make all patients into guinea pigs.  What would happen if a large number of patients received treatments that might be useless, and whose harms doubtless exist, but are unknown?  Some, whether they were Democrats or Republicans, whether they supported Mr Trump, Secretary Clinton or someone else in the last election,  might end up here:



So add anyone who might be or ever become a patient to the long list of people who should be worried about a future Trump administration.

Discussion

We could do our usual rant about the revolving door here.   Obviously, the revolving door pheonomenon is a serious conflict of interest, if not form of corruption, that should have no place in our government, particularly in its agencies that are concerned with health care. Similarly, we could rant about how ill-informed and mission-hostile leaders have to take much responsibility for our currently dysfunctional health care system.

It should be no surprise that Mr Trump, a businessman who has no experience in government, and who often seems at ignorant , if not contemptuous of the US Constitution he may be sworn to uphold, would appoint similarly ill-informed and mission-hostile cabinet secretaries and agency leaders.  Ill-informed, mission-hostile leadership of the FDA could harm a lot of patients.  Such an FDA commissioner, acting in concert with other members of an equally ill-informed and mission-hostile Trump administration could do catastrophic damage to patients, citizens the country and the world. 

Maybe we would all be better off if Mr Tump finds something else to do for the next four years.  Maybe he should stick to being executive producer of the Apprentice





read more...

Save During Our Holiday Sale


We've made it a little easier for you to spread some holiday cheer to the makeup lovers on your list. In the spirit of season, we're discounting prices on some of our most popular kits and palettes. This sale is a great way to help your loved ones build their collection or grab something you have been eyeing all year.
Special FX All-Pro Makeup Kit
A $126.95 Value! 
 Special Holiday Price: $99.95

The Special FX All-Pro Makeup Kit contains all the makeup and tools you need to create beginner to advanced makeup applications:

  • Step-by-step pictorial instructions for a variety of special effects looks
  • 8-color palette (3 Mask Covers and 5 Color Cup  colors)
  • 4.5 oz. Latex Clear
  • 1 oz. Squirt Blood
  • Large Powder Puff
  • 2 oz. 3D Clear Gel
  • Stage Blood
  • .5 oz. Coagulated Blood
  • 1 oz. Barrir Spray
  • Crepe Hair
  • 3 full-size Stageline Makeup Brushes
  • Colorset Powder
  • 1 oz. Makeup Remover Lotion
  • 1 oz. Brush Cleaner
  • 1 oz. Spirit Gum Remover
  • Spirit Gum
  • Tooth FX Blood Red
  • Toth FX Nicotine
  • Rigid Collodion
  • Fixitive A
  • 1 oz. Hair White
  • Modeling Putty/Wax
  • Extra Flesh
  • Bruise ProColorRing
  • Stipple Sponge
  • Non Latex Sponges
  • Cotton Swabs
  • 2 Prosthetic Bullet Holes
  • 1 Prosthetic Wound

Celebré Pro-HD Professional Cream Makeup Kit
A $82.95 Value! 
 Special Holiday Price: $67.95
We paired our Celebré Pro-HD Cream Makeup with staple special effects products to create an ideal kit for stage, film, video, and photography. Available in a Caucasian, Dark Complexion, and TV/Video, our Celebré Pro-HD Professional Cream Makeup Kit includes:

  • 7 full-size Celebré Pro-HD Cream Makeup bases
  • 7 Accent Shades
  • 1 oz. Makeup Remover Lotion
  • 1 oz. Latex with applicator
  • 1 oz. Hair White with applicator
  • 7" Black and Brown Pencil Liners
  • Colorset Powder
  • 1 oz. Makeup Putty/Wax
  • Stage Blood
  • Crepe Hair
  • Bruise ProColorRing
  • Spirit Gum
  • 1 oz. Spirit Gum Remover
  • 2 Stipple Sponges
  • Non-Latex Triangular Foam Wedges
  • Velour Powder Puff
  • Professional Powder Brush
  • Stageline Fine Point Brush
  • Stageline Brush 3/16"
  • Step-by-Step pictorial directions for aging and special effects

All Pro Makeup Kit
A $67.95 Value! 
 Special Holiday Price: $54.95

In addition to our Celebré Pro-HD kit, we have also discounted our All Pro Makeup Kits available in either CreamBlend Sticks or StarBlend Cake Makeup in Fair, Medium, Olive, Dark Complexion, or TV/Video shades. Each kit contains:




  • 5 full-size CreamBlend Sticks or StarBlend Cake Makeup
  • 6 Accent Shades
  • 1 oz. Makeup Remover Lotion
  • 1 oz. Latex with applicator
  • 1 oz. Hair White with applicator
  • 7" Black and Brown Pencil Liners
  • Colorset Powder
  • 1 oz. Makeup Putty/Wax
  • Stage Blood
  • Crepe Hair
  • Bruise ProColorRing
  • Spirit Gum
  • 1 oz. Spirit Gum Remover
  • 2 Stipple Sponges
  • Non-Latex Triangular Foam Wedges
  • Velour Powder Puff
  • Professional Powder Brush
  • Stageline Fine Point Brush
  • Stageline Brush 3/16"
  • Step-by-Step pictorial directions for aging and special effects
Paradises Makeup AQ 30 Color Palette
A $105.00 Value! 
 Special Holiday Price: $84.95

A kaleidoscope of color in a convenient travel case. Body artists will love the transportability of our Paradise Makeup AQ 30 Color Palette. This semi-soft, water activated, and moist makeup delivers rich, bold color.

Limited Edition L.I.P Cream Palette
A $43.95 Value! 
 Special Holiday Price: $27.95

Our Limited Edition L.I.P Cream Palette combines some of our most popular Night and Day shades into one gorgeous palette. Limited quantity. 

Visit www.Mehron.com to start shopping or to create your wish list.

read more...

We're Brightening The Holidays With Gift Bundles

This season there is no need to include a gift receipt. We've put together a bunch of holiday bundles that are sure to brighten the faces of the makeup enthusiasts on your list - literally! Choose from skin prep, hot metallics, and glitz and glimmer to colorful body makeup and gore galore. There is something fabulous for everyone. So start making your list and checking it twice - with these deals you might also want to be your own secret santa.

Fresh Faced Collection
A $62 Val
ue!  Special Holiday Collection Price: $43.95


The Fresh Faced Collection contains everything you need to prep and set any makeup look. Together these products prime the skin and eyelids, banish extra shine, and keep makeup intact so you look fresh longer for that fun night out or a big performance. This great gift collection includes: Skin Prep Pro, Velvet Finish Primer, Primed Eye Primer and Barrier Setting Spray.
Blissful Beauty Collection
A $125 Value!
 Special Holiday Collection Price: $87.95. 
The perfect products to create a flawless complexion were bundled together for our Blissful Beauty Collection. Antioxidant rich Velvet Finish Primer creates a beautiful canvas and extends the wear of our Celebré Pro-HD 12 Color Cream Foundation Palette, which you can apply with unbelievable ease using the Face Smoothie. Finish with a mist of Barrier Spray and you are set for the day. 
Powder Perfect Collection
A $125 Value! 
 Special Holiday Collection Price: $87.95 

For those who prefer a matte finish, we created our Powder Perfect Collection. With Skin Prep Pro, Celebré Pro-HD 12 Color Powder Foundation Palette, Touch Up Anti-Shine Gel, and Kabuki Brush Applicator you can prime, mattify, and set your foundation for a flawless finish. 
Metallic Mania Collection
A $56 Value!
  Special Holiday Collection Price: $38.95 

We've made it easy to add some shimmer with the Metallic Mania Collection. These metallic shades can be applied wet or dry to highlight, shadow, line, and even paint into your hair! The collection includes Metallic Powder (Gold, Silver, and Lavender), our famous Mixing Liquid, Fine Point Detail Makeup Brush, and a 3/16" Flat End Makeup Brush. 
Glitz and Glimmer Collection
A $75 Value!
  Special Holiday Collection Price: $52.95 

You'll find extra sparkle and shine in our Glitz and Glimmer Collection. Precious Gem Powder and paradise Glitter instantly jazz up any beauty look. Use them alone to highlight or on top of your favorite eye shadow or lip color. The collection includes: Precious Gem Powder (Diamond, Champagne, and Bronzite) Paradise Makeup AQ Glitter (Glitter Gold and Silver White), Primed Eye Primer, Fine Point Detail Makeup Brush, and a 3/16" Flat End Makeup Brush. 
Colorize It! Collection
A $76 Value!
  Special Holiday Collection Price: $52.95 
Our Colorize It! Collection is the perfect bundle for face and body painters. It includes all the basic colors and tools necessary to bring any holiday character to life: Paradise Makeup AQ 8 Color Palette, Paradise Makeup AQ Glitter in Gold, GlitterMark Makeup in White, Bold Round Paradise Makeup AQ Brush, Super Fine Paradise Makeup AQ Brush, and a Teal Paradise Sponge Applicator. 
Prisma Spectrum Collection
A $101 Value! 
 Special Holiday Collection Price: $70.95 
Capture all the colors in the rainbow with the Prisma Spectrum Collection. The unique cakes enable quick application by allowing artists to load up multiple colors at a time. With one swipe you can blend rows of color to create stunning designs. Bundle contains Four Paradise Makeup AQ Prisma Cakes (Arc-En-Ciel, Furry, Sunset, and Breeze), Prisma Large 1" Paradise Makeup AQ Brush, Prisma Medium 3/4" Paradise Makeup AQ Brush, and a Prisma Small 1/2" Paradise Makeup AQ Brush.
Gore Galore Collection
A $30 Value!
  Special Holiday Collection Price: $20.95 
For all the horror lovers we have combined our three most popular special effects products in the Gore Galore Collection. From beginners to masters, these staple products deliver top results: Clear 4.5 oz. Liquid Latex, 2 oz. Clear 3-D Gel, and 4.5 oz. Bright Arterial Stage Blood.

All products in this special holiday sale are available for purchase at www.Mehron.com.

We also have some of our popular palettes and kits on sale


  • Special Effects Makeup Kit $99.95 - You save $27.00
  • Celebré Professional Makeup Kit $67.95 - You save $15.00
  • All-Pro Makeup Kit $54.95 - You save $13.00
  • Paradise Makeup AQ 30 Color Palette $84.95 - You save $20.05
  • Limited Edition L.I.P Cream Palette $27.95 - You save $16.00

Visit our site for more holiday specials!


read more...
Home - About - Order - Testimonial
Copyright © 2010 . All Rights Reserved.